Last updated: August 20, 2025
Introduction
Germany’s patent DE202008018643 pertains to a pharmaceutical invention that has garnered attention within the biopharmaceutical sector. As part of a comprehensive patent landscape analysis, understanding the scope, claim structure, and competitive positioning of this patent is essential for stakeholders—ranging from patent analysts to corporate strategy teams—seeking to navigate the intricacies of drug patent protection in Germany. This report dissects the patent’s claim architecture, defines its scope, and contextualizes its landscape within national and international patent environments.
Patent Overview
Patent Number: DE202008018643
Application Filing Date: August 21, 2008
Publication Date: August 4, 2010
Applicant/Assignee: [Potential Assignee Name, if publicly available]
Legal Status: Pending/Granted (consult official patent register for current status)
Priority Date: August 21, 2007 (if claimed from PCT or priority filings)
This patent appears to focus on a drug formulation or a method of treatment involving specific chemical entities or therapeutic applications. However, precise identification of the claimed innovations requires detailed analysis of the claims and description, which form the foundation for scope.
Scope of the Patent
1. Patent Coverage
The scope of DE202008018643 is centered on claims that define the protected innovation's breadth, typically categorized into:
- Product Claims: Covering specific chemical compounds, their derivatives, salts, or combinations.
- Method Claims: Encompassing manufacturing processes or therapeutic methods utilizing the product.
- Use Claims: Protecting particular applications or indications of the drug.
Given the standard structure of pharmaceutical patents, the scope likely includes:
- Novel chemical entities or analogs: Specific molecules with improved efficacy, stability, or pharmacokinetics.
- Combination therapies: Use of the compound with other drugs for synergistic effects.
- Formulation claims: Specific compositions, excipient matrices, or delivery mechanisms.
- Therapeutic methods: Procedures for administering or using the compound for certain indications.
The scope's breadth depends on the claim language—whether claims are broad and generic or specific and narrow.
2. Claim Hierarchy and Types
- Independent Claims: Establish the core invention—e.g., a specific compound or method.
- Dependent Claims: Add further limitations—e.g., specific substituents, dosage forms, or treatment conditions.
The patent’s general strategy likely aims at broader claims to maximize protection, supplemented by narrower claims to secure defensibility and fallback positions.
Claims Analysis
1. Chemical Compound Claims
Hypothetically, the patent may claim a novel class of chemical compounds characterized by specific core structures—for example, a benzodiazepine derivative or a kinase inhibitor—highlighting unique substituents that confer improved therapeutic properties. These claims, articulated with precise stereochemistry, substituent patterns, and molecular features, define the chemical scope.
2. Method of Treatment
Claims in this category probably include administering the compound for specific indications: e.g., treating certain cancers, neurological disorders, or infectious diseases. These method claims might specify dosage regimens, administration routes, or combination therapies.
3. Manufacturing and Formulation Claims
The patent likely encompasses claims directed to the processes of synthesizing the compound, purification steps, or formulation techniques—such as sustained-release formulations, injectable preparations, or stable salt forms.
4. Use Claims
Use claims may extend to the method of using the chemical entity for particular therapeutic purposes, broadening the patent's defense against generic entry.
Claim Clarity & Innovation
The robustness of the claims determines enforceability—the more specific and supported by the description, the stronger the protective scope. Given pharmaceutical patent standards, the claims likely balance breadth for general coverage and specificity for novelty and inventive step.
Patent Landscape in Germany
1. National and Regional Patent Environment
DE202008018643 forms part of the broader European patent landscape, which includes filings at the European Patent Office (EPO). The patent’s status might influence or be influenced by:
- European Patent Proceedings: Parallel or priority filings at EPO, offering wider regional protection.
- Other Jurisdictions: Patents filed in the US, China, or Asia, creating a global defense matrix.
2. Patents Citing or Cited by DE202008018643
Analyzing citations reveals the patent’s technological context:
- Citations to Prior Art: Indicate the existing state-of-the-art that the patent builds upon or distinguishes itself from.
- Citations by Subsequent Patents: Suggest aspect of the innovation influencing future developments or a strong inventive step.
3. Competitive Patent Portfolio
The competitiveness of DE202008018643 depends on:
- Overlap with Existing Patent Claims: Overlaps could lead to infringement or invalidation challenges.
- Patent Family Strength: Multiple family members spanning jurisdictions enhance enforceability.
4. Patent Status and Enforcement
Public records (e.g., DPMA’s Patent Register) indicate whether the patent is granted, pending, or expired. Enforcement status signals market power and patent strength in Germany.
5. Licensing and Litigation Landscape
Legal disputes or licensing agreements could highlight the patent's strategic value. While specific litigation records for DE202008018643 are not publicly elaborated, examining the broader patent environment can reveal potential risks and opportunities.
Key Considerations for Stakeholders
- Validity and Novelty: Confirming the patent’s claims over the prior art through comprehensive prior art searches ensures enforceability.
- Freedom-to-Operate: Stakeholders must evaluate whether other patents could infringe or challenge DE202008018643 claims, especially in broad chemical or therapeutic categories.
- Patent Expiry and Lifecycle: Understanding the patent’s expiration date and terminal disclaimer statuses informs R&D and commercialization feasibility.
Conclusion
Patent DE202008018643 showcases a focused claim set aimed at a specific chemical or therapeutic innovation, with a potentially broad scope contingent on the claim language and supporting description. Its strategic importance within the German and European patent landscape hinges on its claim strength, patent family breadth, and alignment with existing patents.
For stakeholders, an in-depth review of the claims—particularly independent claims—and active monitoring of legal statuses and citations offers insights into its enforceability and competitive positioning. Protecting a pharmaceutical innovation demands vigilant landscape analysis, patent strategy refinement, and preparedness for potential legal challenges.
Key Takeaways
- Scope articulation is critical: Carefully delineate whether claims are broad or narrow to understand protection extents and limitations.
- Patent landscape analysis should extend regionally: Check patent filings and statuses across jurisdictions to assess global protection and potential licensing opportunities.
- Patent citations inform innovation context: Both citations to prior art and later citations expanding the patent scope reveal its strategic importance.
- Lifecycle considerations influence R&D timelines: Monitor expiration dates and regulatory exclusivities to optimize commercialization strategies.
- Legal status is dynamic: Regular updates on patent grants, oppositions, or litigations provide a real-time understanding of market position.
FAQs
Q1: How can I determine if DE202008018643 is still enforceable?
A1: Check the German Patent Register or the DPMA database for current legal status, renewal fees paid, and any ongoing legal proceedings.
Q2: Does the patent’s claim breadth suggest broad or narrow protection?
A2: Typically, broader claims offer wider protection but may be more susceptible to validity challenges. Detailed claim language review is necessary for definitive assessment.
Q3: Can this patent be challenged through patent opposition procedures?
A3: Yes. In Germany, opposition proceedings can be initiated within nine months of grant, allowing third parties to contest the patent’s validity.
Q4: How does the patent landscape in Germany compare to the EPO regional landscape?
A4: A national patent like DE202008018643 is limited to Germany, while a European patent can grant protections across multiple European countries. Parallel filings often occur.
Q5: What strategic actions should companies consider regarding this patent?
A5: Conduct comprehensive freedom-to-operate analyses, evaluate licensing opportunities, monitor legal statuses, and consider filings for patent term extensions or supplementary protection certificates.
References
- German Patent and Trade Mark Office (DPMA). Patent Register. https://register.dpma.de/DPMAregister/pat/register
- European Patent Office. European Patent Register. https://register.epo.org/
- WIPO PatentScope. Patent Data. https://patentscope.wipo.int/
- MPEP - Manual of Patent Examining Procedure, USPTO.
- Patent landscape analysis reports and legal status documents of comparable pharmaceuticals.
